New combo therapy aims to fight hard-to-treat prostate cancer

NCT ID NCT06228053

Recruiting now Disease control Sponsor: Syntrix Biosystems, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug combination (SX-682 plus enzalutamide) in 53 men with metastatic castration-resistant prostate cancer that has worsened despite prior treatments. The goal is to see if the combination can shrink tumors, lower PSA levels, or keep the cancer stable for at least 6 months. Participants will be monitored for side effects and survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Duke University
RECRUITING

Durham, North Carolina, 27710, United States
University of California, Los Angeles
RECRUITING

Los Angeles, California, 90095, United States
University of California, San Francisco
RECRUITING

San Francisco, California, 94143, United States
University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States
University of Minnesota
NOT_YET_RECRUITING

Minneapolis, Minnesota, 55455, United States
University of Wisconsin
RECRUITING

Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.